Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI

To learn whether FDG PET/CT and DCE MRI are better predictors of response to therapy than the current standard of care (CT or MRI).

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : F-18 Fluoro-deoxi-glucose
  • drug : Gadolinium-DTPA
  • drug : Sunitinib
  • procedure : DCE MRI
  • procedure : FDG PET CT

Phase: N/A

Eligibility

Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Measurable disease by RECIST criteria - Pathologic diagnosis of renal cell cancer - Advanced (stage IV) renal cell cancer - Karnofsky performance status of (KPS>70) - Consent to participate in the clinical trial

External Links

Explore related trials

Contact information

Primary Contact:

Andrew Quon 6507361369

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: